Krintafel (tafenoquine succinate) NDC 0173-0889

NDC codes

FDA NDC Directory

Product NDC (as listed)0173-0889Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00173-0889Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0173-0889-39	00173088939	2 TABLET, FILM COATED in 1 BOTTLE (0173-0889-39)Marketed from Jan 22, 2019

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Krintafel
Generic name (nonproprietary): tafenoquine succinate
Active ingredients: Tafenoquine succinate — 150 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: GlaxoSmithKline LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 210795
Marketing start: Jan 22, 2019
Listing expires: Dec 31, 2027
Identifiers: Product ID 0173-0889_d400b994-abe7-40a6-a7bd-0fbf45f855adSPL ID d400b994-abe7-40a6-a7bd-0fbf45f855adSPL set ID 5cf989d5-36f5-4561-a30b-9fcb9deb6b6aRxCUI 2109233, 2109239UNII DL5J0B8VSSUPC 0301730889393

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400173088939 followed by a unit qualifier and the quantity

Package 00173-0889-39. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 2, 2023.

Indications (excerpt from the label)

KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving chloroquine therapy for acute P. vivax infection [see Dosage and Administration ( 2.2 )] . Limitations of Use • KRINTAFEL is NOT indicated for the treatment of acute P. vivax malaria. • Concomitant use of KRINTAFEL with antimalarials other than chloroquine is not recommended because of the risk of recurrence of P. vivax malaria [see Warnings and Precautions ( 5.6 )] . KRINTAFEL is an antimalarial indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving chloroquine t…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)